Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.
A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negat...
Autors principals: | Laura Wendt, Antje Albring, Sven Benson, Harald Engler, Andrea Engler, Anke Hinney, Winfried Rief, Oliver Witzke, Manfred Schedlowski |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Public Library of Science (PLoS)
2014-01-01
|
Col·lecció: | PLoS ONE |
Accés en línia: | http://europepmc.org/articles/PMC4164653?pdf=render |
Ítems similars
-
Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond.
per: Tunbridge, E, et al.
Publicat: (2006) -
VAL158MET catechol O-methyltransferase polymorphism contributes to the development of preeclampsia
per: Tamara Sljivancanin Jakovljevic, et al.
Publicat: (2020-10-01) -
Subjective reward processing and catechol-O- methyltransferase Val158Met polymorphism as potential research domain criteria in addiction: A pilot study
per: Nico Rohlfing, et al.
Publicat: (2022-10-01) -
Human plasma homocysteine levels are associated with the catechol-O-methyltransferase Val158Met polymorphism
per: Tunbridge, E, et al.
Publicat: (2007) -
Association between the Catechol O-methyltransferase (COMT) Val158met polymorphism and different dimensions of impulsivity.
per: Leandro Fernandes Malloy-Diniz, et al.
Publicat: (2013-01-01)